TBPH

TBPH Operating Expenses

$88.59MTTM · USD

Period ending:

TBPH FY Operating ExpensesUSD
TBPH FY Operating Expenses2011-12-31: $120.35M2012-12-31: $139.72M2013-12-31: $156.51M2014-12-31: $240.17M2015-12-31: $219.37M2016-12-31: $226.22M2017-12-31: $269.48M2018-12-31: $298.41M2019-12-31: $325.33M2020-12-31: $369.48M2021-12-31: $119.44M2022-12-31: $79.91M2023-12-31: $72.84M2024-12-31: $73.69M2025-12-31: $115.20M$369.48M$0.00
2011-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

TBPH operating expenses history

Expenses from normal business operations (SG&A, R&D, etc.). The available annual fiscal periods series contains 15 observations from Dec 31, 2011 to Dec 31, 2025.

Theravance Biopharma Inc Operating Expenses — Annual fiscal periods (USD)
Period endingOperating Expenses (USD)
115,195,000
73,687,000
72,838,000
79,911,000
119,438,000
369,484,000
325,329,000
298,406,000
269,479,000
226,221,000
219,368,000
240,169,000
156,510,000
139,720,000
120,345,000

Compare operating expenses

All TBPH financial metrics · TBPH stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.